Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
NCT ID: NCT00424710
Last Updated: 2014-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
17 participants
INTERVENTIONAL
2007-01-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
NCT01884597
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
NCT01248117
Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
NCT01271426
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
NCT01469156
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
NCT00470977
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm study
Single arm study:
Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
ranibizumab intravitreal injection
liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ranibizumab intravitreal injection
liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 25 years
* Polypoidal Choroidal Vasculopathy as noted on fluorescein and ICG angiography: active leakage, active bleeding or recent decrease in vision
* BCVA using ETDRS 20/32 to 20/400
Exclusion Criteria
* Previous cataract or ocular surgery within 2 months of day 0
* Active intraocular inflammation in the study eye
* Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
* Participation with another investigational drug within the past 30 days
* Prior sodium pegaptanib, verteporfin photodynamic therapy, intravitreal steroids, or bevacizumab within 30 days of study entry
* Blood pressure \>180/110 (use of antihypertensives is allowed as long as hypertension can be controlled and is stable)
* Pregnancy
25 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Hawaii Pacific Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gregg T. Kokame, MD
Medical Director, The Retina Center at Pali Momi
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregg T Kokame, MD
Role: PRINCIPAL_INVESTIGATOR
The Retina Center at Pali Momi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Consultants of Hawaii
Honolulu, Hawaii, United States
The Retina Center at Pali Momi
‘Aiea, Hawaii, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol. 2010 Mar;94(3):297-301. doi: 10.1136/bjo.2008.150029. Epub 2009 Sep 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FVF3934s
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.